Chipscreen Biosciences, Ltd.

This phase 3 study tests whether a combination of three drugs (tucidinostat, sintilimab, and bevacizumab) can help people with a specific type of advanced colorectal cancer (MSS/pMMR) live longer. Participants must have already tried at least two standard treatments without succe…

This study tests whether adding the drug tucidinostat to standard chemotherapy (CHOP) can help people with a rare type of lymphoma (PTCL-TFH) live longer without their cancer getting worse. About 224 adults with newly diagnosed disease will be randomly assigned to get either tuci…

This study is testing a new drug called CS23546 in people with advanced solid tumors or lymphoma that have not responded to or cannot tolerate standard treatments. The main goals are to find a safe dose and understand how the drug works in the body. About 156 participants will ta…

This study tests an experimental pill called CS32582 for adults with moderate to severe plaque psoriasis. It has two parts: a small dose-finding phase and a larger 12-week treatment phase. The goal is to see if the drug safely reduces skin symptoms like redness and scaling. About…